KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Ionis Pharmaceuticals (IONS) over the last 11 years, with Q3 2025 value amounting to -$3.9 million.

  • Ionis Pharmaceuticals' Asset Writedowns and Impairment fell 73548.39% to -$3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.6 million, marking a year-over-year decrease of 18896.21%. This contributed to the annual value of $3.0 million for FY2024, which is 8254.06% up from last year.
  • Ionis Pharmaceuticals' Asset Writedowns and Impairment amounted to -$3.9 million in Q3 2025, which was down 73548.39% from $236000.0 recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Asset Writedowns and Impairment peaked at $2.0 million during Q4 2024, and registered a low of -$3.9 million during Q3 2025.
  • In the last 5 years, Ionis Pharmaceuticals' Asset Writedowns and Impairment had a median value of $323000.0 in 2021 and averaged $304578.9.
  • In the last 5 years, Ionis Pharmaceuticals' Asset Writedowns and Impairment surged by 173636.36% in 2021 and then crashed by 73548.39% in 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Asset Writedowns and Impairment (Quarter) stood at $1.6 million in 2021, then plummeted by 43.8% to $875000.0 in 2022, then dropped by 7.2% to $812000.0 in 2023, then surged by 149.14% to $2.0 million in 2024, then plummeted by 294.76% to -$3.9 million in 2025.
  • Its Asset Writedowns and Impairment was -$3.9 million in Q3 2025, compared to $236000.0 in Q2 2025 and $61000.0 in Q1 2025.